Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $5.9 million.

  • Ironwood Pharmaceuticals' Other Non-Current Assets fell 22.93% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 22.93%. This contributed to the annual value of $5.9 million for FY2024, which is 64.16% up from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Other Non-Current Assets stood at $5.9 million, which was up 64.16% from $3.6 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Other Non-Current Assets high stood at $5.9 million for FY2024, and its period low was $847,000 during FY2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Other Non-Current Assets averaged around $3.5 million, with its median value being $3.6 million (2023).
  • In the last 5 years, Ironwood Pharmaceuticals' Other Non-Current Assets declined by 15.30% in 2022 and then skyrocketed by 325.97% in 2023.
  • Ironwood Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $943,000 in 2020, then climbed by 6.04% to $1.0 million in 2021, then fell by 15.30% to $847,000 in 2022, then skyrocketed by 325.97% to $3.6 million in 2023, then surged by 64.16% to $5.9 million in 2024.